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Objective: To analyze changes in the therapeutic 
approach at a tertiary care hospital following 
the implementation of a clinical guideline for 
the treatment of primary vesicoureteral reflux 
(VUR) in children.
Population and methods: Retrospective study 
conducted in a cohort of patients with primary 
VUR (1989-2015) aged 0-15 years at a tertiary care 
hospital. The therapeutic approach before and 
after the development of the clinical guideline 
(2008) was compared.
Results: A total of 297 patients (49.8% boys, 50.2% 
girls) were included; their mean age at the time 
of diagnosis was 21.71 months. VUR grading 
was: VUR I-III 45.1%, VUR IV-V 54,9%; 124 were 
treated after the implementation of the clinical 
guideline (group 1), and 173, before (group 2). 
The mean follow-up period was 124.32 months. A 
conservative approach was the initial treatment 
in 70.3% of group 1 patients and 67.9% of group 2 
patients. The number of surgeries remains 
constant (31.45% versus 31.79%), with an increase 
in the number of endoscopic surgeries (p < 0.005). 
The profile of patients has changed based on the 
application of the algorithm proposed by the 
guideline. Fewer surgeries were done in patients 
with VUR IV-V (82.32% versus 59.9%, p= 0.000) 
and there were fewer cases of kidney damage at 
diagnosis (49.4% versus 9.8%, p= 0.000).
Conclusions: The implementation of the clinical 
guideline has favored an initially conservative 
approach in patients with severe grade VUR 
and nephropathy, for whom surgery was 
traditionally indicated initially. Using clinical 
guidelines favors a unanimous, evidence-
based approach that reduces the performance 
of unnecessary invasive procedures.
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Primary vesicoureteral reflux 
(VUR) is a heterogeneous process 
d e f i n e d  a s  r e t r o g r a d e ,  n o n -
physiological flow of urine from 
the urinary bladder into the ureter, 
without an anatomic or neurological 
cause.1,2 It is a common reason for 
consultation at the departments 
of Pediatric Nephrology, General 
Pediatrics,  Pediatric Surgery or 
Pediatric Urology.
The traditional approach to VUR 
has been based on two fundamental 
a l t e r n a t i v e s :  a n a t o m i c  a n d 
functional correction with surgery 
or conservative management based 
on general hygiene measures and 
antibiotic prophylaxis while waiting 
for spontaneous resolution. In 2008, 
the first Clinical Practice Guideline 
(CPG) for primary VUR in children 
was developed through the Health 
Guideline (Guía Salud) project. 
The CPG lays the foundations for 
the management of VUR based on 
scientific evidence,3 promotes patient 
sequential management (Figure 1), and 
assesses the effectiveness of different 
therapeutic strategies, their ability 
to reduce the number of urinary 
tract infections (UTIs) and, most 
importantly, their ability to protect the 
renal parenchyma and, secondarily, 
long-term kidney function. The CPG 
was updated in 2014 (Figure 2).4
Although most guidelines and 
consensus advocate a conservative 
management as the therapy of choice, 
and its modification based on the 
development of recurrent febrile UTI 
or risk factors, such as kidney injury 
or dilated VUR,5 still some health 
care providers indicate a surgical 
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approach as initial treatment for primary VUR.3 
Eight years after the publication of the CPG, not 
sufficient studies have been conducted to assess 
the impact of the guideline implementation 
so it was decided to analyze the therapeutic 
approach developed in a tertiary care hospital 
following the implementation of the CPG 
recommendations proposed in 2008 and reviewed 
in the 2014 update.4
MATERIAL AND METHODS
This was a retrospective study with patients 
diagnosed with primary VUR, aged 0-15 years, 
following antenatal ultrasound findings or a 
UTI episode, seen at a referral pediatric urology 
facility in the Community of Aragón (Spain), 
between 1989 and 2015.
Patients were divided into group 1 (diagnosed 
as of 2008) and group 2 (diagnosed before 2008). 
Patients with concomitant kidney-urologic 
disease, including renoureteral duplicity, 
urethral stricture, pyeloureteral junction stenosis, 
unilateral renal agenesis, neurogenic bladder, and 
bladder exstrophy, were excluded.
Figure 1. Therapeutic diagnostic algorithm for the management of primary vesicoureteral reflux in children based on the 
Clinical Practice Guideline from 20083
DIC: direct isotope cystography. CcI: creatinine clearance. B/VD: bladder or voiding dysfunction. GFR: glomerular filtration rate. 
UTI: urinary tract infection. M-alb: microalbuminuria. RN: reflux nephropathy. PCr: plasma creatinine.
VUR: vesicoureteral reflux. BP: blood pressure. US: ultrasound.
INITIATION CLINICAL CONTROL TREATMENTS
•  VUR grade I-III: 
no prophylaxis
•  VUR grade IV-V:  
prophylaxis for 1 year or up  
to the next cystography
•  Determine: 
PCr, Ccl or estimated GFR, 
M-alb or proteinuria and 
alpha-1-microglobulin in 
case of RN
Inform caregivers of warning 
signs:
•  Fever without a source of 
infection
•  Dysuria
•  Increased urinary frequency
•  Painful urination
Confirm UTI:  
strip test, urine culture,  
urinary sediment
•  Presence of phimosis
•  Clinical signs of B/VD
•  In case of UTI: 
antibiotics
•  Phimosis: 
treat if VUR > III
•  Study and treat B/VD
Control with DIC in 
asymptomatic VUR
• VUR grade I-III: 
after 2-3 years
• VUR grade IV-V: 
with prophylaxis, 
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All patients were diagnosed with VUR by 
means of a serial voiding cystourethrography 
(VCUG) and c lass i f ied according to  the 
international VUR grading.6 VUR grade I-III was 
considered low grade VUR and VUR grade IV-V, 
high grade VUR. 
Kidney damage was assessed with a renal 
scintigraphy or scan with dimercaptosuccinic 
acid (DMSA) labeled with Tc99m and classified as 
per Goldraich’s classification.7 Renal impairment 
was defined as a reduction in differential renal 
function below 45%8 in this test. Outcome 
measures were collected from the patients’ medical 
records, including sex, age at diagnosis, VUR 
grade, nephropathy at diagnosis –understood 
as the presence of kidney scarring in the renal 
scintigraphy–,4 bilaterality, voiding abnormalities, 
therapeutic sequence used, and type of intervention.
Statistical analysis: the software used for this 
study was PASW Statistic v.18.0.0 (SPSS  Inc.). 
Pearson’s χ² test was done for the study’s 
qualitative outcome measures. Kruskal-Wallis non-
parametric test was applied for the quantitative 
outcome measures. The level of confidence for the 
different tests was established at 95%.
RESULTS
Three hundred and twenty-three patients were 
referred with a diagnosis of primary VUR; of 
these, 26 were excluded because of pyeloureteral 
duplicity (21), pyeloureteral junction stenosis (4), 
and urethral stricture (1). A total of 297 patients 
were included in this study, with a proportion of 
41.8% (124) of patients corresponding to the 2008-
2015 period and 58.2% (173) of patients treated 
before 2008.
Seventy-one percent of patients had a 
diagnosis of primary VUR detected because of 
a UTI, whereas 29% were diagnosed because 
hydronephrosis was observed in the antenatal 
ultrasounds.
Pat ients ’  mean  age  a t  d iagnos i s  was 
21.71 months. The proportion of boys and girls 
in our overall sample was 49.8% and 50.2%, 
respectively.
Also, 45.1% had mild-moderate VUR at the 
time of diagnosis (grade I-III) and 54.9%, severe 
VUR (grade IV-V). In terms of location, 50.2% of 
patients had unilateral VUR and 49.8%, bilateral 
VUR, which accounted for a total of 297 treated 
patients and 445 refluxing units.
Fifty percent of patients had some extent of 
renal damage (nephropathy at diagnosis).
The follow-up period of the overall sample was 
124.32 months (~10.36 years). As for the therapeutic 
approach for each group (Table 1), no statistically 
significant differences were observed in the 
percentage of patients for whom the therapeutic 
diagnostic algorithm proposed by the CPG was 
applied, i.e., initially conservative treatment of 
VUR, with a proportion of 70.97% in group 1 and 
67.63% in group 2 of patients managed with this 
strategy. In relation to the number of surgeries, 
a higher proportion of endoscopic surgery in 
group 1 was observed (p= 0.000).
Once the profile of patients treated in each 
group is analyzed (Table 2), and taking into 
account the clinical characteristics –age at 
diagnosis, reason for diagnosis, VUR grade, 
bilaterality, nephropathy at diagnosis–, it is 
observed that group 1 had a higher percentage 
of patients diagnosed with antenatal ultrasound, 
although most patients in both groups were 
diagnosed following one or several febrile UTI 
episodes. In relation to VUR grade at diagnosis, 
among patients with grade IV-V, the percentage 
of patients for whom conservative treatment was 
not indicated was significantly higher in group 2 
compared to group 1 (82.32% versus 59.9%, 
p= 0.000). Likewise, the percentage of patients 
with nephropathy and initially conservative 
treatment was higher in group 1 than in group 2 
(49.4% versus 39.8%, p= 0.000). In relation to 
age, although there were significant differences 
overall, given the trend towards antenatal 
diagnosis observed in group 1, no significant 
differences were identified between both groups 
in terms of bilaterality.
Table 1. Therapeutic procedures done in groups 1 and 2 (N: 297)
Therapeutic approach Group 1 (2008-2015) Group 2 (1989-2008) p (95% CI χ2) 
 (N: 124) (N: 173)
Sequential therapy 88 (70.97%) 117 (67.63%) p= 0.627
Anti-reflux surgery 39 (31.45%) 55 (31.79%) p= 1.000
Open surgery 4 (3.23%) 31 (17.92%) p= 0.000
Endoscopic surgery 31 (25.83%) 24 (13.87%) p= 0.000
VUR: vesicoureteral reflux; CI: confidence interval.
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DISCUSSION
T h e  f i r s t  n a t i o n a l  g u i d e l i n e  f o r  t h e 
management of primary VUR in children was 
developed by the Health Guideline project, 
whose objective was to standardize treatment 
guidelines and, through their dissemination, help 
to harmonize therapeutic-diagnostic criteria and 
promote evidence-based practice.3 Once results 
obtained as of 2008 are compared, it is observed 
that a high percentage of patients had undergone 
sequentia l  therapy before  the  guidel ine 
implementation. This evidences that physicians 
and surgeons working in our hospital followed, 
based on available evidence and the accumulated 
experience, a conservative approach to VUR in 
their everyday practice and that, as of 2008, the 
number of patients treated conservatively has 
remained practically consistent. Bias is easily 
identified because the guideline’s authors are 
mostly health care professionals from our field of 
work; therefore, this analysis would have greater 
validity if carried out in facilities not related to the 
development of this area.
In relation to the number of surgeries, the 
percentage of patients who were operated has 
not changed significantly. This is the result of 
a previous eminently conservative approach, 
so no reduction was expected in the number 
of surgeries. It has also been observed that 
the surgical technique of choice shifted to a 
greater percentage of endoscopic surgery at 
present. However, authors consider that the 
CPG itself has not encouraged the performance 
of endoscopic surgeries but the improvement in 
several factors, such as the technique itself, the 
materials used, and hospital accessibility, among 
others. Undoubtedly a longitudinal analysis 
of the study involves time as a factor in this 
phenomenon, and it is considered that outcomes 
are the consequence of said bias.
The analysis of the profile of patients treated 
in each group showed significant differences 
in multiple outcome measures, which were 
considered relevant.
The first change was the higher proportion 
of patients with antenatal diagnosis observed 
in group 1 compared to group 2. However, 
although such difference is significant, it cannot 
be attributed to the CPG itself; it should be 
interpreted as the result of better antenatal 
diagnoses, which increase the percentage of 
congenital hydronephrosis and, as a result, the 
number of children diagnosed with VUR referred 
to the Department of Pediatric Urology, and most 
likely subjected to screenings.
In spite of the notably conservative approach 
applied in group 2, this study reveals that the 
traditional concept of surgery as the therapy of 
choice to prevent kidney damage in patients with 
increased risk for unfavorable clinical course, 
high-grade VUR, and nephropathy at diagnosis8-11 
is, and still is for some health care professionals, 
the cause for the selection of surgery as the initial 
therapeutic option for these patients. It has 
been observed how, in spite of a trend towards 
conservative treatment in the pre-guideline 
era, patients with VUR IV-V and nephropathy 
at diagnosis tended to be excluded from the 
sequential treatment algorithm. Little by little, the 
proportion of children with these characteristics 
treated with sequential treatment has increased 
from 34.48% among patients in group 2 with 
Table 2. Treatment received by each type of patient according to their clinical profile (N: 297)
Clinical outcome measures Group 1 (2008-2015) Group 2 (1989-2008) p (95% CI χ2)
   N= 124  N= 173
   CT (N= 88) ST (N= 36) CT (N= 117) ST (N= 56) 
Reason for diagnosis
 Antenatal dx 38.64% 44.44% 17.95% 26.79% p = 0.002
 Febrile UTI 61.36% 55.56% 82.05% 73.21% 
VUR grade
 I-III 54.65% 41.67% 52.14% 17.86% p = 0.000
 IV-V 45.35% 58.33% 47.86% 82.14% 
Age at diagnosis 23.1 months 34.6 months 33.5 months 24.3 months p = 0.027
Nephropathy at diagnosis 49.43% 63.64% 35% 75% p = 0.000
Bilaterality 51.14% 47.22% 43.59% 62.5% p = 0.134
CT: conservative treatment; ST: surgical treatment; dx: diagnosis; UTI: urinary tract infection;
VUR: vesicoureteral reflux.
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nephropathy at diagnosis and sequential therapy 
to 49.43% in group 1.
In relation to VUR grade, it has been observed 
how, despite the highly similar percentage of 
patients with severe VUR in both groups, there 
is a marked trend in the group where surgery is 
selected as the initial treatment. Thanks to the 
recommendations made in the clinical guideline, 
VUR grade itself does not appear to be the reason 
for performing a surgery on a patient; however, 
other factors are assessed, such as recurrent UTIs. 
At present, a higher percentage of children with 
these characteristics are treated with an initially 
conservative approach.
In the last decade, conservative treatment, 
based on hygiene measures and nocturnal 
antibiotic  prophylaxis, 12-14 has definitely 
positioned as the initial treatment of choice. The 
effectiveness of this therapeutic strategy and, 
most importantly, its ability to protect the renal 
parenchyma and, secondarily, long-term kidney 
function, have been repeatedly weighed up and 
analyzed.
The systematic reviews by Wheeler et al.14 
and Nagler et al.15 highlight three clinical assays 
that attempted to elucidate the effectiveness 
of surgical and conservative treatment and 
the advantages of one over the other in terms 
of permanent kidney damage. These are the 
International Reflux Study in Children (IRSC),16 
the Birmingham Reflux Study (Great Britain), and 
the Swedish Reflux Trial in Children.9,13 Results 
showed no differences in the total number of 
recurrent UTIs between both treatment strategies 
at 2, 5 or 10 years of follow-up and in the risk of 
developing new renal parenchymal injuries, the 
progression of existing parenchymal defects, 
and overall kidney growth. The incidence of 
arterial hypertension (AHT) or end-stage renal 
disease (ESRD) in the follow-up of both types of 
patients was similar.
The evidence obtained from studies like the 
ones mentioned above has led, at present, to treat 
primary VUR based on a conservative approach 
and, consecutively, advance to surgical treatment 
–with endoscopic technique as the first choice– in 
the case of recurrent UTIs, always maintaining 
an individualized approach, treating bladder 
dysfunction, and using complementary, non-
invasive tests for the follow-up of asymptomatic 
patients.9
Following 2008, the CPG was updated in 
2014 (Figure 2);4 its drafting included an analysis 
of the CPG by the National Institute for Health 
and Care Excellence (NICE) from 2013,17 the CPG 
for the management of VUR by the American 
Urological Association (AUA)18 from 2010, 
the CPG for the management of UTI by the 
Spanish Association for Pediatric Nephrology 
(Asociación Española de Nefrología Pediátrica, 
AENP) from 2011,19 the CPG by the American 
Academy of Pediatrics from 2011,20 and the CPG 
by the European Association of Urology (EAU) 
from 2012.21
Based on the bibliography available at that 
time and, fundamentally, the publication of the 
Randomized Intervention for Children with 
Vesicoureteral Reflux (RIVUR) project,22-24 some 
of the initial guidelines have been modified, 
especially in relation to nocturnal antibiotic 
prophylaxis. Compared to the algorithm proposed 
in 2008,3 the universal indication has been 
Table 3. Antibiotic prophylaxis recommendations proposed in the clinical guideline based on scientific evidence
Antibiotic prophylaxis is recommended for girls with VUR grade III-V during 1 year  
or until a new cystographic control is done to determine VUR grade again.  B
Antibiotic prophylaxis is recommended for boys with VUR grade IV-V during 1 year  
or until a new cystographic control is done to determine VUR grade again.  √
As a general rule, the group would recommend to assess antibiotic prophylaxis individually,  
considering any factor that may influence the development of new UTIs and  
once parents or caregivers are informed of its risks and benefits.  √
B recommendation: evidence made up of studies classified as 2 ++, directly applicable to the guideline’s target population and 
showing a high level of inter-study consistency; or evidence extrapolated from studies classified as 1 ++ or 1 +.
√: consensus by the drafting team.
Antibiotic prophylaxis: nitrofurantoin or trimethoprim-sulfamethoxazole, unless it is specifically contraindicated or in case of 
resistance observed in urine cultures and sensitivity tests. Dosage: 1/3 of the daily dose by mg/kg. 
UTI: urinary tract infection; VUR: vesicoureteral reflux.
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replaced by a prudent, individualized approach, 
with the recommendation of prophylaxis for 
girls with VUR III-V and boys with VUR IV-V 
for 1 year or until a new cystographic control is 
done to determine VUR grade, as well as among 
patients with bladder dysfunction and recurrent 
UTIs, always with an individualized assessment 
of the risks and benefits of this strategy (Table 3).
The use of generalized prophylaxis has 
become increasingly restricted in the different 
recommendations made by scientific societies; 
however, its indications are still controversial. 
In the latest update of the Argentine Society of 
Pediatrics,25 chemoprophylaxis is indicated for 
infants younger than 1 year with the first UTI 
episode if no imaging studies have been done 
yet and with any grade VUR, older children 
with VUR grade III or higher, regardless of sex, 
children with scarring and VUR, in the presence of 
bladder dysfunction and VUR, and patients who 
undergo screening tests because of, e.g., antenatal 
hydronephrosis, in whom VUR is detected.
Figure 2. Therapeutic diagnostic algorithm for the management of primary vesicoureteral reflux in children based on the 
updated Clinical Practice Guideline from 20144
DIC: direct isotope cystography. CcI: creatinine clearance. B/VD: bladder or voiding dysfunction. GFR: glomerular filtration rate.  
UTI: urinary tract infection. M-alb: microalbuminuria. RN: reflux nephropathy. BP: blood pressure.
CAP: continuous antibiotic prophylaxis. PCr: plasma creatinine. VUR: vesicoureteral reflux. US: ultrasonography..
INITIATION CLINICAL CONTROL TREATMENTS
No CAP: 
VUR grade I-III in boys 
VUR grade I-II in girls
CAP:
VUR grade IV-V in boys 
VUR grade III-V in girls 
1 year or up to the next 
cystography
Determine: 
PCr, CcI or estimated GFR, 
M-alb or proteinuria and 
alpha-1-microglobulin  
in case of RN
Inform parents of warning 
signs:
Fever without a source of 
infection  




strip test, urine culture,  
urinary sediment
Explore for the presence of 
phimosis
Supervise for clinical signs 
of B/VD
In case of UTI: antibiotics
Phimosis: assess individually 
in VUR > III and recurrent 
UTIs
Warning in case of clinical 
signs of B/VD
Study and treat B/VD 
Covert bacteriuria:  
do not treat
Control with DIC in 
asymptomatic VUR
• VUR I:
no control with DIC
• VUR II-III: 
after 2-3 years
• VUR IV-V: 
with CAP, after 1 year;
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following surgery
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Another controversial aspect observed in the 
latest updates refers to the different methods 
used for VUR diagnosis and follow-up. The 2014 
update still advocates the serial VCUG is the 
method of choice for VUR diagnosis because of 
its optimal anatomic definition,4 highlighting 
the role of indirect cystography as the method of 
choice for control given its lower level of radiation 
compared to the serial VCUG, its lower reliance 
on technical equipment and observers, and its 
lower cost compared to cystosonography.26
However, other scientific societies, such as 
the Argentine Society of Pediatrics25 or the AUA 
in 2011,18 have proposed to initiate the diagnostic 
algorithm with an ultrasound.
These  indicat ions  are  not  considered 
contradictory because most patients seen in 
our outpatient offices have generally had an 
ultrasound, either antenatally or following the 
first febrile UTI, as recommended by the CPG 
for the management of UTI in the pediatric 
population by the AENP.19  An ultrasound 
should be the test of choice for those patients 
referred without one because, in spite of its 
low sensitivity to detect VUR20 and scarce cost-
effectiveness published by some authors,27 its 
sensitivity is much higher to detect urinary tract 
dilation and anatomic abnormalities, and poses 
the advantage of not using radiation and being 
a fast, inexpensive method for VUR screening.28
Although the implementation of these 
guidelines may be complicated because of the 
different public health settings where they are 
used –e.g., according to the AGREE analysis, 
reviewers of the CPG subject of our study 
considered that the applicability of the CPG 
proposed by the AUA was only 25%–3 therefore, 
restricting its dissemination, their development 
is encouraged because, as observed in our study, 
the therapeutic approach becomes more uniform, 
gains greater scientific soundness, and improves 
health care quality.
In our case, adherence to the CPG has made 
it possible for us to maintain these patients’ 
management updated, has favored the selection 
of a conservative treatment for patients with 
severe and congenital VUR, which resulted in a 
reduction in the number of aggressive procedures 
in these patients, and has promoted the gradual 
implementation of necessary measures based on 
scientific evidence. n
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